Analysts at Oppenheimer provided their views on Frequency Therapeutics, Inc. (NASDAQ:FREQ) following their discussion with the company’s management regarding recent progress and anticipated milestones.

The new Ph2b 208 study is going well and the company expects to complete patient enrollment (N=124) in Q3/22, with top-line data expected in Q4/22 or early-2023.

At the recent R&D event, the company disclosed two new clinical candidates from the proprietary PCA platform. The follow-on molecule for hearing loss, FX-345, is expected to enter the clinic in the second half of this year with data expected in the first half of 2023. For the MS program, the company will select a candidate in 2022 and start a clinical trial in 2023.

According to the analysts, the company's $160 million cash and cash equivalents as of the end of Q3/21 should provide a financial runway into year-end 2023.